DOI: http://dx.doi.org/10.18203/issn.0019-5359.IndianJMedSci20170492

Detection of p53 exon 9 gene mutation in bladder cancer by polymerase chain reaction-single-strand conformation polymorphism method

Mojdeh Abbasi, Mohammad Hossein Mirmomeni, Sedigheh Khazaei, Reza Ranjbaran

Abstract


Introduction: Urinary bladder cancer is the fourth most common diagnosed malignancy in men and the tenth in women worldwide. The successful treatment depends on early detection and specific diagnostic approaches. Mutations in the p53 tumor suppressor gene (TP53) are very common among the cancers, especially in bladder cancer that p53 mutation is identified in around 60 percents. Aims: In this study, we aim to detect p53 mutation in bladder cancer patients in Kermanshah city of Iran. 

Materials and Methods: Thirty paraffin-embedded specimens were obtained from bladder cancer patients. They were reviewed by pathologists for substantial amounts of neoplastic tissue. PCR-SSCP technique was used followed by standard silver staining to analyze TP53 exon 9 gene mutations in tumor samples. 

RESULTS: Polyacrylamide gel analysis represented mutations in 2 cases (6.7%) that were classified as p53-positive, and there were no mutations in 28 cases (93.3%) that were classified as p53-negative. No significant correlation observed between p53 mutation and histological grade, tumor stage, muscular propria status, patient sex, and age. 

Conclusion: These data are the first report on the p53 abnormalities in bladder cancer patients from Kermanshah. We can suppose that the percentage of p53 exon 9 mutation is low in bladder cancer patients from western Iran. However, further studies on a large number of tissue specimens, if possible, help to verify the obtained results.


Keywords


Bladder cancer, mutation, p53, polymerase chain reaction, single-strand conformation polymorphism

Full Text:

PDF

References


Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.

Mazzucchelli R, Morichetti D, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, et al. Neuroendocrine tumours of the urinary system and male genital organs: Clinical significance.BJU Int 2009;103:1464-70.

Ross RK, Jones PA, Yu MC. Bladder cancer epidemiology and pathogenesis. Semin Oncol 1996;23:536-45.

Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997;3:621-4.

Bonnal C, Ravery V, Toublanc M, Bertrand G, Boccon-Gibod L, Hénin D, et al. Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology 2000;55:287-91.

Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000;85:614-7.

Friedrich MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer. J Urol 2000;163:1039-42.

Phillips HA, Howard GC, Miller WR. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer 2000;82:136-41.

Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson HH, et al. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004;90:1572-6.

Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney DM. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 2004;91:552-7.

p53 mutations: All cancer. Available from: http://p53.free.fr/Database/p53_cancer/all_cancer.html. [Last accessed on 2013 Oct 10].

Vousden KH, Lu X. Live or let die: The cell’s response to p53. Nature Reviews Cancer 2002;2:594-604.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.

Pluquet O, Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 2001;174:1-15.

Hussain SP, Hofseth LJ, Harris CC. Tumor suppressor genes: At the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001;34 Suppl 2:S7-15.

Dalbagni G, Ren ZP, Herr H, Cordon-Cardo C, Reuter V. Genetic alterations in tp53 in recurrent urothelial cancer: A longitudinal study. Clin Cancer Res 2001;7:2797-801.

Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene 1995;10:1493-9.

Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.

Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998;52:79-98.

Soussi T, Béroud C. Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. Human Mutat 2003;21:192-200.

Freed-Pastor WA, Prives C. Mutant p53: One name, many proteins. Genes Dev 2012;26:1268-86.

Ling B, Wei-Guo Z. p53: Structure, function and therapeutic applications. J Cancer Mol 2006;2:141-53.

LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, et al. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 2000;21:101-6.

Schlichtholz B, Presler M, Matuszewsk M. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast. Carcinogenesis 2004;25:2319-23.

Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor1 JA. p53 mutations in bladder cancer: Evidence for exogenous versus endogenous risk factors. Cancer Res 2003;63:7530-38.

Scoggan KA, Bulman DE. Single-strand conformational polymorphism analysis (SSCP) and sequencing for ion channel gene mutations. Methods Mol Biol 2003;217:143-51.

Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olafsdottir K, Agnarsson BA, et al. TP53 mutation analyses on breast carcinomas: A study of paraffin-embedded archival material. Br J Cancer 1996;74:555-61.

Bautista S, Theillet C. p53 mutations in breast cancer: Incidence and relations to tumor aggressiveness and evolution of the disease. Pathol Biol (Paris) 1997;45:882-92.

Borkowska E, Binka-Kowalska A, Constantinou M, Nawrocka A, Matych J, Kałuzewski B. P53 mutations in urinary bladder cancer patients from Central Poland. J Appl Genet 2007;48:177-83.

Kusser WC, Miao X, Glickman BW, Friedland JM, Rothman N, Hemstreet GP, et al. p53 mutations in human bladder cancer. Environ Mol Mutagen 1994;24:156-60.

Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006;45:715-9.

Lorenzo Romero JG, Salinas Sánchez AS, Giménez Bachs JM, Sánchez Sánchez F, Escribano Martínez J, Hernández Millán IR, et al. p53 gene mutations in superficial bladder cancer. Urol Int 2004;73:212-8.




 
Home     |     Articles in Press     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     
       
       

Indian Journal of Medical Sciences, Quarterly, published by Medip Academy.     
This is an open-access journal, published articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.

website: www.ijmsweb.com   editorial contact: editor@ijmsweb.com

© Medip Academy. All Rights Reserved.